Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Felberbaum

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Human Reproduction (Oxford, England)|February 25, 2000
Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study GroupC Albano, R E Felberbaum, J Smitz, et al.
Fertility and Sterility|February 13, 2001
Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelixM Ludwig, H Riethmüller-Winzen, R E Felberbaum, et al.
Human Reproduction (Oxford, England)|April 28, 2000
Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III studyR E Felberbaum, C Albano, M Ludwig, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|August 1, 1995
Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertilityR E Felberbaum, T Reissmann, W Küpker, et al.
Archives of Gynecology and Obstetrics|September 14, 2000
Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproductionM Ludwig, R E Felberbaum, P Devroey, et al.
Reproductive Biomedicine Online|March 25, 2004
Previous miscarriages influence IVF and intracytoplasmatic sperm injection pregnancy outcomeM S Kupka, C Dorn, M Montag, et al.
Human Reproduction (Oxford, England)|August 4, 1998
Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist CetrorelixR E Felberbaum, U Germer, M Ludwig, et al.
Archives of Gynecology and Obstetrics|May 10, 2002
Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVFM Ludwig, C Albano, F Olivennes, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Human Reproduction (Oxford, England)|February 25, 2000
Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study GroupC Albano, R E Felberbaum, J Smitz, et al.
Fertility and Sterility|February 13, 2001
Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelixM Ludwig, H Riethmüller-Winzen, R E Felberbaum, et al.
Human Reproduction (Oxford, England)|April 28, 2000
Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III studyR E Felberbaum, C Albano, M Ludwig, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|August 1, 1995
Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertilityR E Felberbaum, T Reissmann, W Küpker, et al.
Archives of Gynecology and Obstetrics|September 14, 2000
Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproductionM Ludwig, R E Felberbaum, P Devroey, et al.
Reproductive Biomedicine Online|March 25, 2004
Previous miscarriages influence IVF and intracytoplasmatic sperm injection pregnancy outcomeM S Kupka, C Dorn, M Montag, et al.
Human Reproduction (Oxford, England)|August 4, 1998
Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist CetrorelixR E Felberbaum, U Germer, M Ludwig, et al.
Archives of Gynecology and Obstetrics|May 10, 2002
Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVFM Ludwig, C Albano, F Olivennes, et al.
Pageof 2